Human-derived, plant-produced monoclonal antibody for the treatment of anthrax.
The unpredictable nature of bio-terrorism compels us to develop medical countermeasures that will enable authorities to treat individuals exposed to agents such as anthrax. We report the feasibility of producing a protective, human-derived, monoclonal antibody directed against the protective antigen (PA) of Bacillus anthracis in plants. This was achieved by transient expression using agroinfiltration of Nicotiana benthamiana plants. The resulting antibody was able to neutralize toxin activity in vitro and in vivo at a comparable level to that seen for its hybridoma-produced counterpart.
Hull
Anna K
AK
Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way Suite 200, Newark, Delaware, DE 19711, USA.
Criscuolo
Carolyn J
CJ
Mett
Vadim
V
Groen
Herman
H
Steeman
Wilma
W
Westra
Hans
H
Chapman
Gail
G
Legutki
Bart
B
Baillie
Les
L
Yusibov
Vidadi
V
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000235:genetics; D001408:Bacillus anthracis / Q000235:genetics / Q000276:immunology; D001427:Bacterial Toxins / Q000235:genetics; D001483:Base Sequence; D002460:Cell Line; D004274:DNA, Recombinant / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008805:Mice, Inbred A; D009500:Neutralization Tests; D030821:Plants, Genetically Modified; D014026:Nicotiana / Q000235:genetics
D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D004274:DNA, Recombinant; C030325:anthrax toxin